Instituto Rosenbusch (BUE:ROSE) Research & Development: ARS0 Mil (TTM As of Dec. 2025)


BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
39 GF Score
Price ARS162.00
GF Value ARS61.70
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Research & Development?

Instituto Rosenbusch BUE:ROSE +0.93% 39 Research & Development is ARS0 Mil as of Dec. 2025. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS61.70 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Instituto Rosenbusch's Research & Development for the three months ended in Dec. 2025 was ARS0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was ARS0 Mil.

Instituto Rosenbusch  (BUE:ROSE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Instituto Rosenbusch Research & Development Related Terms

Instituto Rosenbusch Research & Development Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Research & Development Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Instituto Rosenbusch Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BUE:ROSE
39GF Score
Instituto Rosenbusch SA BUE:ROSE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Instituto Rosenbusch Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ARS0 Mil mean?
Instituto Rosenbusch (BUE:ROSE) has a Research & Development of ARS0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's Research & Development too high?
Instituto Rosenbusch's current Research & Development is ARS0 Mil. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Research & Development compare to ZTS and UTHR?
Instituto Rosenbusch's Research & Development of ARS0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current Research & Development is ARS0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.70, compared to a current price of ARS162.00 — trading 162.6% above its estimated fair value. The current Research & Development is ARS0 Mil. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Research & Development is ARS0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS162.00 is trading 162.6% above its estimated GF Value™ of ARS61.70. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Research & Development: ARS0 Mil
  • GF Value™: ARS61.70 vs. price of ARS162.00 (162.6% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score

Get the complete analysis for BUE:ROSE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS162.00
Price
ARS61.70
GF Value